CRISPR-Cas9 Treatment for People with Genetic Disorders
DOI:
https://doi.org/10.58445/rars.3453Keywords:
CRISPR/Cas9, Genetic disorders, Gene editingAbstract
CRISPR/Cas 9 is a new gene editing technology that can make precise changes in DNA. The CRISPR method is based on a natural system used by bacteria to protect themselves from viruses. It has shown great potential in treating genetic disorders: Down syndrome, by targeting extra copies of chromosome 21; sickle cell disease, by correcting mutations in the beta-globin gene to restore fetal hemoglobin; and CPS1 (Carbamoyl Phosphate Synthetase 1) deficiency, by fixing mutations that cause toxic accumulation of ammonia in the body. While CRISPR is a promising tool, the technology is still considered relatively new and can be further developed. This review aims to analyze the potential applications of CRISPR from the cellular level to real-life medical treatment, as well as the concerns of its usage. The paper also discusses each application of CRISPR in a range of genetic disorders. Understanding these aspects is crucial for future research and ensuring responsible implementations of CRISPR in medicine. One recent CRISPR advancement, including the first FDA-approved CRISPR-based therapy(Casgevy) and eventually, there will be further development using CRISPR.
References
Al-Ouqaili, Mushtak T S, et al. “Harnessing Bacterial Immunity: CRISPR-Cas System as a Versatile Tool in Combating Pathogens and Revolutionizing Medicine.” Frontiers in Cellular and Infection Microbiology, vol. 15, 2025, p. 1588446, pubmed.ncbi.nlm.nih.gov /40521034/, https://doi.org/10.3389/fcimb.2025.1588446.
American Society of Hematology. “Sickle Cell Disease.” American Society of Hematology, American Society of Hematology, 2021, www.hematology.org/education/patients/anemia/sickle-cell-disease.
Asmamaw, Misganaw, and Belay Zawdie. “Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing.” Biologics: Targets and Therapy, 21 Aug. 2021, www.dovepress.com/mechanism-and-applications-of-crisprcas-9-mediated-genome-editing-peer-reviewed-fulltext-article-BTT.
Ayanoglu, Fatma Betul. “Bioethical Issues in Genome Editing by the CRISPR/Cas9 Technology.” Turkish Journal of Biology, vol. 44, no. 2, 2 Apr. 2020, pp. 110–120, www.ncbi.nlm.nih.gov/pmc/articles/PMC7129066/, https://doi.org/10.3906/biy-1912-52.
Barrangou, Rodolphe, and Luciano A. Marraffini. “CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity.” Molecular Cell, vol. 54, no. 2, Apr. 2014, pp. 234–244, https://doi.org/10.1016/j.molcel.2014.03.011.
Boston Children's Hospital. “CASGEVY (Exagamglogene Autotemcel) | Boston Children’s Hospital.” Www.childrenshospital.org, 2025, www.childrenshospital.org/treatments/casgevy.
Children's Hospital of Philadelphia. “World’s First Patient Treated with Personalized CRISPR Gene Editing Therapy at Children’s Hospital of Philadelphia.” Chop.edu, 15 May 2025, www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital.
Choi, Yunha, et al. “Unfavorable Clinical Outcomes in Patients with Carbamoyl Phosphate Synthetase 1 Deficiency.” Clinica Chimica Acta, vol. 526, Feb. 2022, pp. 55–61, https://doi.org/10.1016/j.cca.2021.11.029.
Cleveland Clinic. “Down Syndrome.” Cleveland Clinic, 31 Jan. 2023, my.clevelandclinic.org/health/diseases/17818-down-syndrome.
Davies, Benjamin. “The Technical Risks of Human Gene Editing.” Human Reproduction, vol. 34, no. 11, 6 Nov. 2019, https://doi.org/10.1093/humrep/dez162.
Hashizume, Ryotaro, et al. “Trisomic Rescue via Allele-Specific Multiple Chromosome Cleavage Using CRISPR-Cas9 in Trisomy 21 Cells.” PNAS Nexus, vol. 4, no. 2, 1 Feb. 2025, academic.oup.com/pnasnexus/article/4/2/pgaf022/8016019?login=false, https://doi.org/10.1093/pnasnexus/pgaf022. Accessed 2 Mar. 2025.
Henderson, Hope, and Jodi Halpern. “CRISPR & Ethics.” Innovative Genomics Institute (IGI), Innovative Genomics Institute, 21 Nov. 2024, innovativegenomics.org/crisprpedia/crispr-ethics/.
HMS COMMUNICATIONS. “Creating the World’s First CRISPR Medicine, for Sickle Cell Disease.” Harvard.edu, 20 Feb. 2025, hms.harvard.edu/news/creating-worlds-first-crispr-medicine-sickle-cell-disease.
Hsu, Patrick D., et al. “Development and Applications of CRISPR-Cas9 for Genome Engineering.” Cell, vol. 157, no. 6, June 2014, pp. 1262–1278, www.ncbi.nlm.nih.gov/pmc/articles/PMC4343198/, https://doi.org/10.1016/j.cell.2014.05.010.
Kolata, Gina. “Baby Is Healed with World’s First Personalized Gene-Editing Treatment.” The New York Times, 15 May 2025, www.nytimes.com/2025/05/15/health/gene-editing-personalized-rare-disorders.html.
“Mie University R-Navi-|Innovative Approach Developed for Removing Extra Chromosome 21 in Cells from Individuals with down Syndrome Using CRISPR-Cas9 Genome Editing Technology.” Mie University - R-Navi , 2025, www.mie-u.ac.jp/en/R-navi/release/medic/innovative-approach-developed-for-removing-extra-chromosome-21-in-cells-from-individuals-with-down-s.html.
Murdock, Andy. “First Patient Treated with Personalized CRISPR Therapy, Developed in Just Six Months.” Innovative Genomics Institute (IGI), 15 May 2025, innovativegenomics.org/news/first-patient-treated-with-on-demand-crispr-therapy/.
Musunuru, Kiran, et al. “Patient-Specific in Vivo Gene Editing to Treat a Rare Genetic Disease.” New England Journal of Medicine, vol. 392, no. 22, 15 May 2025, https://doi.org/10.1056/nejmoa2504747.
Sternberg, Samuel H., et al. “DNA Interrogation by the CRISPR RNA-Guided Endonuclease Cas9.” Nature, vol. 507, no. 7490, 29 Jan. 2014, pp. 62–67, https://doi.org/10.1038/nature13011.
The. “The Future of Personalized Medicine Is Here: KJ’s Story.” Chop.edu, 2025, www.chop.edu/centers-programs/genetherapy4inheritedmetabolicdisorders/future-personalized-medicine-here-kjs.
Wikipedia Contributors. “Cas9.” Wikipedia, Wikimedia Foundation, 13 Apr. 2019, en.wikipedia.org/wiki/Cas9.
Wu, Katherine J. “Crispr Gene Editing Can Cause Unwanted Changes in Human Embryos, Study Finds.” The New York Times, 31 Oct. 2020, www.nytimes.com/2020/10/31/health/crispr-genetics-embryos.html.
Wells, Jackson. “In Vitro vs in Vivo: A History of Modern Cell Culture.” Emulate, 16 Feb. 2024, emulatebio.com/in-vitro-vs-in-vivo-cell-culture/.
Arun, Adith. “Understanding the Science behind the Gene Editing Treatment for Baby KJ.” Aditharun.com, Adith Arun, 17 July 2025, www.aditharun.com/p/understanding-the-science-behind. Accessed 9 Oct. 2025
Downloads
Posted
Categories
License
Copyright (c) 2025 Suri Nguyen
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
